From randomized trial to practice: Single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1772-1778

  Aletti, G D ^a   Nordquist, D ^a   Hartmann, L ^a   Gallenberg, M ^a   Long, H J ^a   Cliby, W A ^a  

^a MAYO CLINIC   (United States)

Author keywords

I.p. chemotherapy; Ovarian cancer; Quality of care; Toxicity

Indexed keywords

CISPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CATHETER INFECTION; CATHETERIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; HUMAN; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NUTRITIONAL STATUS; OVARY CARCINOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CROSS-SECTIONAL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAPERITONEAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77956098870     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq025     Document Type: Article

References (22)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
2. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986; 13: 219-243
3. McClay EF, Howell SB. A review: intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol Oncol 1999; 36: 1-6.
4. Markman M, Francis P, Rowinsky E, Hoskins W. Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer? Semin Oncol 1995; 22: 84-87.
5. Howell SB, Pfeifle CL, Wung WE et al. Intraperitoneal cispaltin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 845-851.
6. Dedrick R, Myers C, Bungay P et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1-11.
7. Kirmani S, Braly PS, McClay EF et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994; 54: 338-344.
8. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-1955.
9. Polyzos A, Tasvaris N, Kosmas C et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999; 56: 291-296.
10. Gadducci A, Carnini F, Chiara S et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologica Nord-Ovest. Gynecol Oncol 2000; 76: 157-162.
11. Yen M-S, Juang C-M, Lai C-R et al. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynecol Obstet 2001; 72: 55-60.
12. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1007.
13. Fung-Kee-Fung M, Provencher D, Rosen B et al. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol 2007; 105(3): 747-756.
14. Vergote I, Amant F, Leunen K et al. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. Oncologist 2008; 13(4): 410-414.
15. Armstrong D, Bundy B, Wenzel L et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
16. National Cancer Institute. NCI Clinical Announcement: Intraperitoneal Chemotherapy for Ovarian Cancer, January 5, 2006. http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf. (30 January 2010, date last accessed).
17. Gore M, Du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006; 24: 4528-4530.
18. Thigpen T, Stuart G, du Bois A et al. Gynecologic Cancer Intergroup; GOG; NCICCTG; AGO-OVAR; ANZGOG; JGOG; GINECO; SGCTG; MRC/NCRI; NSGO; RTOG; GEICO; EORTC. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 2005; 16 (Suppl 8): viii13-viii19.
19. Ozols RF, Bookman MA, du Bois A et al. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 2006; 103(1): 1-6.
20. Naumann RW, Sukumvanich R, Edwards RP. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecol Oncol 2009; 114(1): 37-41.
21. Berry E, Matthews KS, Singh DK et al. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol 2009; 113(1): 63-67.
22. Walker JL, Armstrong DK, Huang HQ et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 2006; 100(1): 27-32.